The latest Moderna vaccine test forwarded for a combination of flu / covid

Moderna announced the beginning of its phase 1/2 human clinical trial involving its seasonal influenza vaccine. The work is the beginning of what can be an interesting evolution of seasonal disease vaccines, with modern, indicating that it plans to evaluate combined vaccines that can offer combined vaccines that would provide protection against RSV, the flu, influenza. COVID-19 and HMPV. 

According to Moderna, the first people participating in his phase 1/2 MRNA-1010 quadrivalent the fluctuated flu candidate trial was dosed with the product. This target candidate vaccine of multiple lines based on the WHO recommendation, including the H1N1 and H3N2 flu, as well as influenza B b B Yamagata and Victoria viruses.

The vaccinal candidate is tested on healthy adults at the age of 18 and over. The 1/2 phase test aims to evaluate the RNAn-1010 vaccine candidate for immunogenicity, reactogenicity and, of course, security. Moderna may intend to register for 180 people in the study.

Although the influenza vaccine plays an important role in the protection of public health, the production of egg-based vaccines is not ideal: the wording is decided up to nine months before vaccines are needed, For example, and their effectiveness falls between 40 – and 60%. MRNA vaccines offer greater potential, moderna notes, to treat respiratory viruses.

These vaccines can combine several different antigens so that a single vaccine provides protection against several types of viruses, as well as businesses could respond more quickly to variations in these respiratory viruses and the needs of the public. The CEO of Moderna Stéphane Bantel explained:

“We believe that the advantages of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses and the ability to rapidly respond to the evolution of respiratory viruses, such as influenza, SARS-CoV-2 and RSV. Our vision is to develop an mRNA combination vaccine so that people can get one shot each fall for high efficacy protection against the most problematic respiratory viruses. We look forward to advancing our core modality of prophylactic mRNA vaccines so that we can continue to make an impact on global public health.”